Synageva Biopharma (GEVA) Misses Q4 EPS, Revenue Views

Synageva Biopharma (NASDAQ: GEVA) reported Q4 EPS of ($0.65), $0.27 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $1.61 million versus the consensus estimate of $1.78 million.

For earnings history and earnings-related data on Synageva Biopharma (GEVA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• MeiraGTx Holdings plc (MGTX) Tops Q2 EPS by 202c
• Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c